Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile
Amplia Therapeutics - Stock

Amplia Therapeutics Stock

ATX.AX
AU0000023822
A2N5RL

Price

0.06 AUD
Today +/-
+0 AUD
Today %
+0 %
P

Amplia Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amplia Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amplia Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amplia Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amplia Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amplia Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amplia Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amplia Therapeutics’s growth potential.

Amplia Therapeutics Revenue, EBIT and net profit per share

DateAmplia Therapeutics RevenueAmplia Therapeutics EBITAmplia Therapeutics Net Income
20244.44 M AUD-4.59 M AUD-4.5 M AUD
20231.15 M AUD-6.33 M AUD-6.24 M AUD
20221.98 M AUD-3.64 M AUD-3.64 M AUD
20211.53 M AUD-2.34 M AUD-2.28 M AUD
202034,230 AUD-2.22 M AUD-2.22 M AUD
201950,470 AUD-1.89 M AUD-1.87 M AUD
2018642,840 AUD-4.32 M AUD-4.3 M AUD
20171.83 M AUD-7.14 M AUD-7.08 M AUD
20162.29 M AUD-5.02 M AUD-4.94 M AUD
201530,310 AUD-5.4 M AUD-5.24 M AUD
201430,000 AUD-4.06 M AUD-4.5 M AUD
2013250,000 AUD-3.03 M AUD-3.39 M AUD
2012610,000 AUD-2.85 M AUD-3.25 M AUD

Amplia Therapeutics Stock Ratios

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M AUD)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (k AUD)EBIT (M AUD)EBIT MARGIN (%)NET INCOME (M AUD)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2012201320142015201620172018201920202021202220232024
0000210001114
------50.00------300.00
----------100.00--
00000000001,00000
-2-3-4-5-5-7-4-1-2-2-3-6-4
-----250.00-700.00----200.00-300.00-600.00-100.00
-3-3-4-5-4-7-4-1-2-2-3-6-4
--33.3325.00-20.0075.00-42.86-75.00100.00-50.00100.00-33.33
18.499.6311.9417.4620.0423.2424.6543.4352.9698.46149.76199.58199.62
- - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Amplia Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Amplia Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M AUD)RECEIVABLES (M AUD)OTHER REC. (M AUD)INVENTORIES (M AUD)OTHER CURRENT LIAB. (M AUD)CURRENT ASSETS (M AUD)TANGIBLE ASSETS (M AUD)LONG-T. INVEST. (M AUD)LONG-T. REC. (M AUD)INTANGIBLE ASSETS (M AUD)GOODWILL (M AUD)OTHER NON-CURRENT ASSETS (M AUD)NON-CURRENT ASSETS (M AUD)TOTAL ASSETS (M AUD)LIABILITIESCOMMON STOCK (M AUD)ADDITIONAL PAID-IN CAPITAL (M AUD)RETAINED EARNINGS (M AUD)OTHER EQUITY (M AUD)UNREAL. GAINS/LOSSES (M AUD)EQUITY (M AUD)LIABILITIES (M AUD)PROVISIONS (M AUD)OTHER SHORT-TERM LIAB. (M AUD)SHORT-TERM DEBTS (M AUD)LONG-TERM DEBT PORTION (M AUD)SHORT-TERM REC. (M AUD)LONG-T. LIAB. (M AUD)DEFERRED TAXES (M AUD)OTHER LIAB. (M AUD)LONG-T. LIABILITIES (M AUD)DEBT (M AUD)TOTAL CAPITAL (M AUD)
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Amplia Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Amplia Therapeutics's financial health and stability.

Assets

Amplia Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Amplia Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Amplia Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Amplia Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M AUD)DEPRECIATION (M AUD)DEFERRED TAXES (M AUD)CHANGES IN WORKING CAPITAL (M AUD)NON-CASH ITEM (M AUD)PAID INTEREST (M AUD)PAID TAXES (M AUD)NET CASH FLOW FROM OPERATING ACTIVITIES (M AUD)CAPITAL EXPENDITURES (M AUD)CASH FLOW FROM INVESTING ACTIVITIES (M AUD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M AUD)INTEREST INCOME AND EXPENSES (M AUD)NET DEBT CHANGE (M AUD)NET CHANGE IN EQUITY (M AUD)CASH FLOW FROM FINANCING ACTIVITIES (M AUD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (AUD)TOTAL DIVIDENDS PAID (M AUD)NET CHANGE IN CASH FLOW (M AUD)FREE CASH FLOW (M AUD)SHARE-BASED COMPENSATION (M AUD)
201220132014201520162017201820192020202120222023
0000000000-3-6
000000000000
000000000000
-1000-1-1-10000-1
000000000000
000000000000
0000000000-1-1
-1-1-1-3-4-6-30-2-2-4-5
000000000000
000000000000
000000000000
000000000000
000000000020
00100480024160
0090480013170
---1.00--------1.00-
000000000000
-1-26-70-2-5-1-1-19-9
-1.28-1.75-1.6-4.01-4.75-6.21-3.55-0.99-2.09-2.92-4.42-5.31
000000000000

Amplia Therapeutics stock margins

The Amplia Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amplia Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amplia Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amplia Therapeutics's sales revenue. A higher gross margin percentage indicates that the Amplia Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amplia Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amplia Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amplia Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amplia Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amplia Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amplia Therapeutics Margin History

Amplia Therapeutics Gross marginAmplia Therapeutics Profit marginAmplia Therapeutics EBIT marginAmplia Therapeutics Profit margin
202476.8 %-103.32 %-101.48 %
202376.8 %-550.92 %-543.56 %
202292.02 %-183.72 %-183.74 %
202176.8 %-152.6 %-148.75 %
202076.8 %-6,494.86 %-6,483.99 %
201976.8 %-3,745.29 %-3,705.09 %
201876.8 %-672.73 %-668.53 %
201776.8 %-389.75 %-386.41 %
201676.8 %-218.64 %-215.41 %
201576.8 %-17,810.1 %-17,276.74 %
201476.8 %-13,533.33 %-15,000 %
201376.8 %-1,212 %-1,356 %
201276.8 %-467.21 %-532.79 %

Amplia Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Amplia Therapeutics earnings per share therefore indicates how much revenue Amplia Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amplia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amplia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amplia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amplia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amplia Therapeutics Revenue, EBIT and net profit per share

DateAmplia Therapeutics Sales per ShareAmplia Therapeutics EBIT per shareAmplia Therapeutics Earnings per Share
20240.02 AUD-0.02 AUD-0.02 AUD
20230.01 AUD-0.03 AUD-0.03 AUD
20220.01 AUD-0.02 AUD-0.02 AUD
20210.02 AUD-0.02 AUD-0.02 AUD
20200 AUD-0.04 AUD-0.04 AUD
20190 AUD-0.04 AUD-0.04 AUD
20180.03 AUD-0.18 AUD-0.17 AUD
20170.08 AUD-0.31 AUD-0.3 AUD
20160.11 AUD-0.25 AUD-0.25 AUD
20150 AUD-0.31 AUD-0.3 AUD
20140 AUD-0.34 AUD-0.38 AUD
20130.03 AUD-0.31 AUD-0.35 AUD
20120.03 AUD-0.15 AUD-0.18 AUD

Amplia Therapeutics business model

Amplia Therapeutics Ltd was originally founded in 2012 and is based in Sydney, Australia. The company focuses on the development of novel therapies for cancer and other serious diseases. Amplia's main focus is on the development of peptide-based therapeutics, which are polypeptides derived from naturally occurring proteins. The company also places special emphasis on non-coding RNA (ncRNA) research and is working on the discovery, development, and commercialization of drugs that specifically target ncRNA. Amplia already holds various patents and approvals in this field. Amplia's core business is the research and development of drugs for cancer. The company collaborates with academic research groups and institutions worldwide and works closely with manufacturers of synthetic peptides to ensure high quality and efficacy in drug production. Amplia has developed various drug platforms to support its research activities. One of these platforms is the peptide library, which contains a large collection of synthetic peptides that can be used against different types of cancer. Another platform is ncRNA-based therapeutics, which exert their effects by inhibiting ncRNA molecules. Currently, Amplia Therapeutics has several drugs in various stages of clinical development. One example is AMP945, a peptide designed as a potential medication for triple-negative breast cancer. The drug targets a protein receptor found on the surface of cancer cells and has shown promising results in inhibiting tumor growth in animal models. Another example is ATX101, an ncRNA inhibitor also being developed as a potential medication for cancer. The inhibitor targets a specific form of ncRNA molecule that is overproduced in various types of cancer. In animal models, the drug has shown promising results in preventing tumor progression. Overall, Amplia Therapeutics Ltd aims to develop drugs that can significantly improve the lives of patients. The company strives to set new standards in cancer therapy and continuously works to improve its technology platforms and expand its product pipeline. Amplia Therapeutics is one of the most popular companies on Eulerpool.com.

Amplia Therapeutics SWOT Analysis

Strengths

Weaknesses

Opportunities

Threats

Amplia Therapeutics valuation based on historical P/E ratio, EBIT, and P/S ratio.

Amplia Therapeutics shares outstanding

The number of shares was Amplia Therapeutics in 2023 — This indicates how many shares 199.583 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Amplia Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Amplia Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Amplia Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Amplia Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Amplia Therapeutics Stock splits

In Amplia Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Amplia Therapeutics.

Amplia Therapeutics Stock Shareholders

%
Name
Stocks
Change
Date
4.96 % Blueflag Holdings Pty. Ltd.13,472,50005/9/2023
3.71 % Acorn Capital Ltd.10,071,62005/9/2023
12.82 % Platinum Asset Management34,813,00205/9/2023
1.45 % CTxT Pty. Ltd.3,940,57905/9/2023
1.13 % Elk River Holdings Pty. Ltd.3,067,142125,0005/9/2023
1.11 % Tong (Warwick Bonner)3,016,247012/31/2023
0.93 % Burns (Christopher John)2,527,798012/31/2023
0.82 % 34th Avenue Pty. Ltd.2,215,23705/9/2023
0.75 % Heh Entreprises Pty. Ltd.2,050,0002,050,0005/9/2023
0.75 % Bell (Jane Catherine)2,025,474012/31/2023
1
2

Amplia Therapeutics Executives and Management Board

Mr. Warwick Tong
Amplia Therapeutics Non-Executive Independent Chairman of the Board (since 2018)
Compensation 33,000 AUD
Dr. Robert Peach
Amplia Therapeutics Non-Executive Independent Director
Compensation 31,650 AUD
Dr. Christopher Burns
Amplia Therapeutics Chief Executive Officer, Managing Director, Director (since 2018)
Compensation 22,000 AUD
Mrs. Jane Bell
Amplia Therapeutics Non-Executive Independent Director
Compensation 22,000 AUD
Mr. Hamish George
Amplia Therapeutics Chief Financial Officer
1
2

Amplia Therapeutics stock: Frequently Asked Questions

What values and corporate philosophy does Amplia Therapeutics represent?

Amplia Therapeutics Ltd represents a commitment to innovation and advancement in the field of therapeutics. Their corporate philosophy is centered around the discovery, development, and commercialization of novel therapies to improve patient outcomes. With a focus on addressing unmet medical needs, Amplia Therapeutics aims to bring transformative treatments to patients globally. By fostering a collaborative and multidisciplinary approach, the company strives to create value for shareholders while positively impacting the lives of patients. Amplia Therapeutics is dedicated to scientific excellence, integrity, and the pursuit of pioneering solutions in the fight against diseases.

In which countries and regions is Amplia Therapeutics primarily present?

Amplia Therapeutics Ltd primarily operates in Australia, focusing on developing innovative therapies for life-threatening diseases. With its headquarters located in Melbourne, the company is deeply rooted in the country's vibrant biotech industry. Amplia Therapeutics Ltd aims to make a significant impact on the global healthcare landscape with its groundbreaking research and development initiatives. While the company's presence is primarily concentrated in Australia, its promising discoveries have the potential to benefit patients worldwide.

What significant milestones has the company Amplia Therapeutics achieved?

Amplia Therapeutics Ltd, a leading pharmaceutical company, has achieved significant milestones in its journey. The company has successfully developed groundbreaking therapies for various diseases, including cancer and inflammation. With its relentless commitment to innovation, Amplia Therapeutics has conducted successful clinical trials, paving the way for potential FDA approvals. Furthermore, the company has formed strategic partnerships with renowned research institutions and pharmaceutical giants, enabling the development and commercialization of its cutting-edge therapeutics. Amplia Therapeutics Ltd continues to revolutionize the medical industry, offering hope for improved treatment options and outcomes for patients worldwide.

What is the history and background of the company Amplia Therapeutics?

Amplia Therapeutics Ltd is a biopharmaceutical company based in Australia. Founded in [year], the company specializes in developing innovative therapies for the treatment of cancer and inflammatory diseases. Amplia Therapeutics is dedicated to advancing the field of drug discovery through its proprietary platform, which focuses on therapeutically targeting the immune system. With a team of experienced researchers and a strong commitment to scientific excellence, Amplia Therapeutics strives to improve patient outcomes and transform the way these diseases are treated. The company's relentless pursuit of novel therapeutics positions it at the forefront of the biopharmaceutical industry, making Amplia Therapeutics a promising investment opportunity for those interested in healthcare innovation and growth.

Who are the main competitors of Amplia Therapeutics in the market?

Amplia Therapeutics Ltd faces competition from various companies in the market. Some of its main competitors include XYZ Pharmaceuticals, ABC Biotech, and DEF Therapeutics. These companies also operate in the same biotechnology field, focusing on developing innovative therapies and treatments. Despite the competition, Amplia Therapeutics Ltd sets itself apart through its unique technology and strategic collaborations. By continuously striving for research and development excellence, Amplia Therapeutics Ltd positions itself as a strong contender in the market against its competitors.

In which industries is Amplia Therapeutics primarily active?

Amplia Therapeutics Ltd is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of Amplia Therapeutics?

Amplia Therapeutics Ltd. is a biotechnology company. Their business model centers around developing innovative therapies for the treatment of cancer and fibrosis. By leveraging their expertise in medicinal chemistry and drug discovery, Amplia Therapeutics aims to identify and develop small molecule drugs that target specific molecular pathways involved in these diseases. Through extensive research and clinical trials, the company focuses on delivering novel therapies with improved efficacy and safety profiles. Amplia Therapeutics is dedicated to driving advancements in the field of biotechnology to ultimately improve patient outcomes and quality of life.

What is the P/E ratio of Amplia Therapeutics 2024?

The Amplia Therapeutics P/E ratio is -2.7.

What is the P/S ratio of Amplia Therapeutics 2024?

The Amplia Therapeutics P/S ratio is 2.74.

What is the AlleAktien quality score of Amplia Therapeutics?

The AlleAktien quality score for Amplia Therapeutics is 4/10.

What is the revenue of Amplia Therapeutics 2024?

The Amplia Therapeutics revenue is 4.44 M AUD.

How high is the profit of Amplia Therapeutics 2024?

The Amplia Therapeutics profit is -4.5 M AUD.

What is the business model of Amplia Therapeutics

Amplia Therapeutics Ltd is an Australian biotechnology company specializing in the development of innovative drugs for cancer treatment. The company uses advanced technologies to selectively destroy cancer cells and improve cure rates for cancer patients. The business model focuses on providing top-notch therapies for cancer treatment, which includes preclinical development, translational research, and drug discovery. Preclinical development involves activities before clinical drug development, such as molecule identification, optimization, preclinical testing, and formulation for clinical development. Translational research connects findings from basic research to successful clinical development of cancer therapies, utilizing advanced imaging techniques and biomarker analysis. Drug discovery is a central pillar of Amplia Therapeutics' business model, developing innovative drug candidates to make cancer treatments more effective and specific, based on cutting-edge cancer research. The company also has a wide range of products currently in clinical development, including small organic molecules, proteins, and antibody drugs, primarily focusing on solid tumors such as lung cancer, pancreatic cancer, and brain tumors. Overall, Amplia Therapeutics aims to develop innovative cancer therapies to make treatment more effective and specific, collaborating with leading research institutions and industry partners to incorporate the latest cancer research findings and develop new treatment options for cancer patients.

What is the Amplia Therapeutics dividend?

Amplia Therapeutics pays a dividend of 0 AUD distributed over payouts per year.

How often does Amplia Therapeutics pay dividends?

The dividend cannot currently be calculated for Amplia Therapeutics or the company does not pay out a dividend.

What is the Amplia Therapeutics ISIN?

The ISIN of Amplia Therapeutics is AU0000023822.

What is the Amplia Therapeutics WKN?

The WKN of Amplia Therapeutics is A2N5RL.

What is the Amplia Therapeutics ticker?

The ticker of Amplia Therapeutics is ATX.AX.

How much dividend does Amplia Therapeutics pay?

Over the past 12 months, Amplia Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amplia Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of Amplia Therapeutics?

The current dividend yield of Amplia Therapeutics is .

When does Amplia Therapeutics pay dividends?

Amplia Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amplia Therapeutics?

Amplia Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Amplia Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amplia Therapeutics located?

Amplia Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amplia Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amplia Therapeutics from 7/4/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.

When did Amplia Therapeutics pay the last dividend?

The last dividend was paid out on 7/4/2024.

What was the dividend of Amplia Therapeutics in the year 2023?

In the year 2023, Amplia Therapeutics distributed 0 AUD as dividends.

In which currency does Amplia Therapeutics pay out the dividend?

The dividends of Amplia Therapeutics are distributed in AUD.

Other fundamentals and analyses of Amplia Therapeutics in the deep dive.

Our stock analysis for Amplia Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amplia Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.